Skip to main content

Table 2 List of all active, completed or terminated clinical trials of mRNA CAR-T cells in cancer therapy

From: mRNA therapeutics in cancer immunotherapy

Sponsor Therapy Indication ClinicalTrial.gov identifier (phase) Combination Opened Status
Cartesian Therapeutics BCMA CAR-T cells (Descartes-08) Multiple myeloma NCT03448978 (I) Fluodarabine and cyclophosphamide pretreatment 2018 Recruiting [156]
The Third Affiliated Hospital of Guangzhou Medical University NKG2D-ligand targeting CAR-NK cells Solid tumors NCT03415100 (I) IL-2 2018 Unknown [157]
University of Pennsylvania Mesothelin CAR-T cells Malignant pleural mesothelioma NCT01355965 (I) None 2011 Completed [158, 159]
Metastatic PDAC NCT01897415 (I) None 2013 Completed [159, 160]
c-MET CAR-T cells Metastatic breast cancer, TNBC NCT01837602 (I) None 2013 Completed [161]
Melanoma, breast cancer NCT03060356 (I) None 2016 Terminated (lack of funding)
CD19 CAR-T cells Hodgkin lymphoma NCT02277522 (I) Interval cyclophosphamide [162] 2014 Terminated (inability to meet enrollment goal) [163]
NCT02624258 (I) Interval cyclophosphamide [162] 2015 Terminated (PI’s decision) [163]
CD123 CAR-T cells Relapsed or refractory AML NCT02623582 (I) Cyclophosphamide pretreatment 2015 Terminated (lack of funding) [164]
  1. From ClinicalTrial.gov (keywords: cancer, mRNA, CAR) on Nov 1, 2020 and PubMed literature research. AML acute myeloid leukemia, BMCA B cell maturation antigen, CAR chimeric antigen receptor; cMET protein kinase Met; IL interleukin, NK natural killer, NKG2D Natural killer group 2D, PDAC pancreatic ductal adenocarcinoma; protein kinase Met, TNBC triple-negative breast cancer